PURPOSE: The analogue 131I-metaiodobenzylguanidine (MIBG), which is specifically targeted to neuroblastoma cells, may provide more effective and less toxic treatment for neuroblastoma than conventional external-beam radiotherapy. We report a dose escalation study of 131I-MIBG to define dose-limiting toxicity without and with autologous bone marrow support. PATIENTS AND METHODS: Thirty patients with relapsed neuroblastoma were treated in groups of six with escalating doses of 3 to 18 mCi/kg of 131I-MIBG. After rapid escalation in the first three patients treated at 3 to 6 mCi/kg, treatment was escalated in 3-mCi/kg increments from 9 to 18 mCi/kg. Autologous tumor-free bone marrow was cryopreserved in all patients receiving 12 mCi/kg and more. Toxicity and response were assessed. RESULTS: Eighty percent of patients who received 12 mC/kg or more experienced grade 4 thrombocytopenia and/or neutropenia. Dose-limiting hematologic toxicity was reached at 15 mCi/kg, at which level two of five assessable patients required bone marrow reinfusion for absolute neutrophil count (ANC) of less than 200/microL for more than 2 weeks, and four of nine at the 18-mCi/kg level. Prolonged thrombocytopenia was common, with failure to become platelet-transfusion independent in nine patients. One patient with extensive prior treatment developed secondary leukemia and three became hypothyroid. Responses were seen in 37% of patients, with one complete response (CR), 10 partial response (PR), three mixed response, 10 stable disease, and six progressive disease. The minimum dose of 131I-MIBG for 10 of the 11 responders was 12 mCi/kg. CONCLUSION: Treatment with 131I-MIBG has mainly hematologic toxicity, which can be abrogated with bone marrow rescue. The high response rate in refractory disease suggests that this agent may be useful in combination with myeloablative chemotherapy and autologous stem-cell rescue to improve outcome in advanced neuroblastoma.
PURPOSE: The analogue 131I-metaiodobenzylguanidine (MIBG), which is specifically targeted to neuroblastoma cells, may provide more effective and less toxic treatment for neuroblastoma than conventional external-beam radiotherapy. We report a dose escalation study of 131I-MIBG to define dose-limiting toxicity without and with autologous bone marrow support. PATIENTS AND METHODS: Thirty patients with relapsed neuroblastoma were treated in groups of six with escalating doses of 3 to 18 mCi/kg of 131I-MIBG. After rapid escalation in the first three patients treated at 3 to 6 mCi/kg, treatment was escalated in 3-mCi/kg increments from 9 to 18 mCi/kg. Autologous tumor-free bone marrow was cryopreserved in all patients receiving 12 mCi/kg and more. Toxicity and response were assessed. RESULTS: Eighty percent of patients who received 12 mC/kg or more experienced grade 4 thrombocytopenia and/or neutropenia. Dose-limiting hematologic toxicity was reached at 15 mCi/kg, at which level two of five assessable patients required bone marrow reinfusion for absolute neutrophil count (ANC) of less than 200/microL for more than 2 weeks, and four of nine at the 18-mCi/kg level. Prolonged thrombocytopenia was common, with failure to become platelet-transfusion independent in nine patients. One patient with extensive prior treatment developed secondary leukemia and three became hypothyroid. Responses were seen in 37% of patients, with one complete response (CR), 10 partial response (PR), three mixed response, 10 stable disease, and six progressive disease. The minimum dose of 131I-MIBG for 10 of the 11 responders was 12 mCi/kg. CONCLUSION: Treatment with 131I-MIBG has mainly hematologic toxicity, which can be abrogated with bone marrow rescue. The high response rate in refractory disease suggests that this agent may be useful in combination with myeloablative chemotherapy and autologous stem-cell rescue to improve outcome in advanced neuroblastoma.
Authors: Steven G DuBois; Louis Chesler; Susan Groshen; Randall Hawkins; Fariba Goodarzian; Hiroyuki Shimada; Greg Yanik; Michael Tagen; Clinton Stewart; Yael P Mosse; John M Maris; Denice Tsao-Wei; Araz Marachelian; Judith G Villablanca; Katherine K Matthay Journal: Clin Cancer Res Date: 2012-03-15 Impact factor: 12.531
Authors: Shih-ying Huang; Wesley E Bolch; Choonsik Lee; Henry F Van Brocklin; Miguel H Pampaloni; Randall A Hawkins; Aimee Sznewajs; Steven G DuBois; Katherine K Matthay; Youngho Seo Journal: Mol Imaging Biol Date: 2015-04 Impact factor: 3.488
Authors: Michael A Kosmin; Jamshed B Bomanji; Nicholas J Cork; Ananth Shankar; Mark N Gaze Journal: Eur J Nucl Med Mol Imaging Date: 2012-01-04 Impact factor: 9.236
Authors: Katherine K Matthay; Alekist Quach; John Huberty; Benjamin L Franc; Randall A Hawkins; Hollie Jackson; Susan Groshen; Suzanne Shusterman; Gregory Yanik; Janet Veatch; Patricia Brophy; Judith G Villablanca; John M Maris Journal: J Clin Oncol Date: 2009-01-26 Impact factor: 44.544
Authors: Kelly E Huibregtse; Kieuhoa T Vo; Steven G DuBois; Stephanie Fetzko; John Neuhaus; Vandana Batra; John M Maris; Brian Weiss; Araz Marachelian; Greg A Yanik; Katherine K Matthay Journal: Eur J Cancer Date: 2016-08-27 Impact factor: 9.162
Authors: Margaret J Zhou; Michelle Y Doral; Steven G DuBois; Judith G Villablanca; Gregory A Yanik; Katherine K Matthay Journal: Eur J Cancer Date: 2015-08-05 Impact factor: 9.162
Authors: Shakeel Modak; Pat Zanzonico; Jorge A Carrasquillo; Brian H Kushner; Kim Kramer; Nai-Kong V Cheung; Steven M Larson; Neeta Pandit-Taskar Journal: J Nucl Med Date: 2016-01-07 Impact factor: 10.057